Apexigen

San Carlos, United States

Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new antibody therapeutics for oncology.

$2.8M raised

Jan 2023

Post-IPO Equity

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Apexigen raised?

Apexigen has raised $2.8M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2023.

Who are Apexigen's investors?

Apexigen's investors include Decheng Capital, 3E Bioventures, Delian Capital, Oceanpine Capital, SV Tech Ventures.

Where is Apexigen headquartered?

Apexigen is headquartered in San Carlos, United States.

What does Apexigen do?

Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new antibody therapeutics for oncology.

What stage is Apexigen at?

Apexigen is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 24, 2023.

MLA

"Apexigen — Funding & Investors." VCBacked, January 24, 2023, https://www.vcbacked.co/company/apexigen. Accessed July 2, 2026.

APA

VCBacked. (2023). Apexigen — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/apexigen

Wikipedia (cite web)

{{cite web |title=Apexigen — Funding & Investors |url=https://www.vcbacked.co/company/apexigen |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 24, 2023.